Einar Wanhainen joins Calissendorff Swarting

We are happy to announce that Einar Wanhainen joins Calissendorff Swarting as partner as per 1 March 2018. For more information about Einar and about the firm, please read the attached press release (in Swedish).

 

Jan-Mikael Bexhed awarded H.M. The King's medal in the 8th size with the Order of the Seraphim ribbon

We are proud to announce that on the 28 of January 2018 the Royal Court announced on www.kungahuset.se that H.M. The King of Sweden has bestowed Calissendorff Swarting partner Jan-Mikael Bexhed with H.M. The King´s medal in the 8th size with the ribbon of the Order of the Seraphim.

Medals bestowed by H.M. The King of Sweden are made to Swedish or foreign citizens who have made outstanding contributions of a humanitarian nature or of general benefit to the society. Bexhed has been bestowed with his medal for considerable efforts as a lawyer and attorney.

 

Opinion column regarding consitutional issues in the government's inquiry on limiting profits of private sector welfare providers

Jan-Mikael Bexhed has co-authored an opinion column in Swedish newspaper Svenska Dagbladet regarding constitutional issues surrounding the Swedish government's proposal on limitation on profits within tax funded welfare services. The proposal which has recently been referred to the Council on Legislation for consideration. The column draws attention to how the proposed profit limitation relates to the constitutionally protected freedom to conduct business. The column can be read here or downloaded as a PDF here (link/PDF will open in a new window).

 

Leave to appeal granted by the Supreme Administrative Court in a dispute between the Church of Sweden and the National Heritage Board

The Supreme Administrative Court (Sw: Högsta förvaltningsdomstolen) has granted the Church of Sweden (the Diocese of Linköping) leave to appeal in a dispute between the Diocese and the National Heritage Board concerning the legal concept of a “church site” (Sw: kyrkotomt) under the Culture Heritage Act of 1988. Jan-Mikael Bexhed is acting as counsel for the Church of Sweden before the Supreme Administrative Court.

 

Opinion column regarding the need for an immunity legislation for foreign works of art

Jan-Mikael Bexhed has co-authored an opinion column in Swedish newspaper Svenska Dagbladet regarding the need for an immunity legislation for the protection of foreign works of art, to facilitate cross-border lending of art between museums. The column can be read here (link will open in a new window).

 

Revision of the Swedish Bar Association's Legal Certainty Program

Jan-Mikael Bexhed has been appointed chairman of a working group of seven prominent attorneys, who will lead the work to review and revise the Swedish Bar Association's Legal Certainty Program, which was launched nearly 30 years ago.

 

Axel Calissendorff appointed special examiner by the board of Eltel AB (publ)

Axel Calissendorff, founding partner, has been appointed special examiner (Sw. särskild granskningsman) by the board of directors of Eltel AB (publ) to investigate potential irregularities behind the considerable need for write-downs reported by the company 21 February 2016.

The special examination report was presented on 1 June 2017.

 

Axel Calissendorff appointed Chair of the Nomination Committee of Recipharm AB (publ)

For the third consecutive year Axel Calissendorff has been appointed Chair of the above Nomination Committee. The task of the committee is to propose elections and remuneration to be passed at the Annual Meeting in the spring of 2018.

 

Calissendorff Swarting assists Swedish Orphan Biovitrum AB (publ)

Calissendorff Swarting assists Swedish Orphan Biovitrum AB (publ) (Sobi) legal department with advice and lawyers for a longer period of time. Camilla Appelgren is primarily Calissendorff Swarting’s responsible partner and is partially present at Sobi headquarters at Karolinska Institutet in Solna. The assignment involves also Peter Nilsson, Martin Nyberg and other lawyers from Calissendorff Swarting.

Sobi is an international specialty healthcare company dedicated to rare diseases with a mission to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within haemophilia. Sobi also markets a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm.

 

Calissendorff Swarting has represented Recipharm AB (publ) in its acquisition of businesses in India, Sweden and the United States of SEK 1.7 billion

Calissendorff Swarting has represented Recipharm AB (publ) in the acquisition of businesses in India, Sweden and the United States for 1.7 billion for the creation of a leading global CDMO (Contract Development and Manufacturing Organization) in the pharmaceutical industry.

 

Calissendorff Swarting has represented Recipharm AB (publ) in its acquisition of a majority share stake in Indian CMO Nitin Lifesciences Ltd for a purchase price of INR 6,713 million (SEK 824 million)

Calissendorff Swarting has represented Recipharm AB (publ) in the acquisition of 74 per cent of the shares in Nitin Lifesciences Limited, an Indian family owned Contract Manufacturing Organisation (CMO) that produces sterile injectables, for a purchase price of INR 6,713 million (SEK 824 million) on a cash and debt free basis. The acquisition was completed on 11 April 2016 following approval from the Indian Foreign Investment Board.

 

Calissendorff Swarting represented Aprea AB in the largest financing of a private equity Swedish Life Science company in a decade

Calissendorff Swarting represented Aprea AB, a subsidiary of Karolinska Development AB, in a SEK 437 million financing.

The financing is the largest private financing to date by any of Karolinska Development's companies portfolio, and more broadly by any Swedish private Life Sciences company in the last decade. The investors consisted of Life Sciences investors Versant Ventures and 5AM (US), Sectoral Asset Management (Canada) and HealthCap (Sweden). Karolinska Development participated via the conversion of outstanding loans.